Position in ABBV
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$210,955,599
+$5,139,158 QoQ
Shares Held
838,323
-11.4% QoQ
Ownership
0.047%
of shares outstanding
% of Portfolio
0.79%
of 13F equity value
Holder Rank
#154
of 4,167 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SEB Asset Management AB holds $2,691,961,669 across 10 Drug Manufacturers - General names. ABBV ranks #5 (7.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
5,736,648 | $1,087,783,193 | |
| 2 | LLY |
ELI LILLY & Co
|
390,198 | $468,015,226 | |
| 3 | JNJ |
Johnson & Johnson
|
1,303,456 | $331,038,720 | |
| 4 | MRK |
Merck & Co., Inc.
|
1,656,056 | $212,803,196 | |
| 5 | ABBV |
AbbVie Inc.
This page
|
838,323 | $210,955,599 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
2,872,632 | $165,521,055 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
836,260 | $105,653,088 | |
| 8 | AMGN |
Amgen Inc
|
169,078 | $61,226,525 |
All Filings in ABBV
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $210,955,599 | 838,323 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $205,816,441 | 946,326 | Shares | Sole | 2026-05-07 | |
| No filing history on record for this holder in this stock. | ||||||